OTCMKTS:IPSEY - IPSEN S A/S Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$41.9010 +0.45 (+1.09 %)
(As of 07/20/2018 04:00 PM ET)
Previous Close$41.9010
Today's Range$41.63 - $41.9010
52-Week Range$28.7724 - $41.74
Volume456 shs
Average Volume1,675 shs
Market Capitalization$13.88 billion
P/E Ratio45.05
Dividend Yield0.53%
Beta0.04
IPSEN S A/S logoIpsen S.A. operates as a pharmaceutical company worldwide. It operates in two segments, Specialty Care and Consumer Healthcare. The company offers drugs in oncology, endocrinology, neurology, gastroenterology, cognitive disorders, and rheumatology areas. Its products include Somatuline, which is an injectable treatment for acromegaly and neuroendocrine tumors; Cabometyx, a tablet formulation of cabozantinib for renal cell carcinoma; Onivyde for metastatic pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, and female sterility; and Dysport for motor disorders and muscular spasticity. The company also provides NutropinAq, a liquid formulation, for treating growth failure in children due to growth hormone deficiency in adults; and Increlex used for long-term treatment of growth failure in children and adolescents. In addition, it offers Smecta, a formulation for use in the treatment of chronic and acute diarrhea; Forlax, an osmotic laxative indicated for the symptomatic treatment of constipation in adults and children; Fortrans for the treatment of intestinal cleaning; Eziclen, an osmotic laxative indicated for the cleaning of bowel; Etiasa for the treatment of inflammatory bowel diseases; and Tanaka for mild cognitive impairment related to age, pathophysiological deficiencies, vertigo, retinal deficits, acute or chronic hearing impairment, and tinnitus. Further, the company provides Adenuric for the treatment of gout; Prontalgine, an analgesic for the treatment of moderate to severe pain; Buscopan, an antispasmodic; Suppositoria Glycerini, a laxative; and Mucothiol and Mucodyne, which are expectorants for cough and flu. Ipsen S.A. has a strategic agreement with Arix Bioscience plc to develop and commercialize various therapies. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy S.A.

Receive IPSEY News and Ratings via Email

Sign-up to receive the latest news and ratings for IPSEY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:IPSEY
CUSIPN/A
Phone33-01-58-33-50-00

Debt

Debt-to-Equity RatioN/A
Current Ratio1.08
Quick Ratio0.90

Price-To-Earnings

Trailing P/E Ratio45.05
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.27 billion
Price / Sales6.17
Cash Flow$1.2916 per share
Price / Cash32.44
Book Value$5.19 per share
Price / Book8.07

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees4,907
Outstanding Shares334,770,000
Market Cap$13,876.13

IPSEN S A/S (OTCMKTS:IPSEY) Frequently Asked Questions

What is IPSEN S A/S's stock symbol?

IPSEN S A/S trades on the OTCMKTS under the ticker symbol "IPSEY."

What is the consensus analysts' recommendation for IPSEN S A/S?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IPSEN S A/S in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."

Who are some of IPSEN S A/S's key competitors?

Who are IPSEN S A/S's key executives?

IPSEN S A/S's management team includes the folowing people:
  • Mr. David D. Meek, CEO & Director (Age 55)
  • Mr. Aymeric Le Chatelier, Exec. VP & CFO (Age 49)
  • Dr. Aidan Murphy, Exec. VP of Technical Operations (Age 52)
  • Dr. Alexandre P. Lebeaut, Exec. VP of R&D and Chief Scientific Officer (Age 61)
  • Ms. Eugenia Litz, VP of Investor Relations

Has IPSEN S A/S been receiving favorable news coverage?

Press coverage about IPSEY stock has trended somewhat positive on Saturday, Accern Sentiment Analysis reports. The research group scores the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. IPSEN S A/S earned a news impact score of 0.07 on Accern's scale. They also gave headlines about the company an impact score of 46.19 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.

How do I buy shares of IPSEN S A/S?

Shares of IPSEY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is IPSEN S A/S's stock price today?

One share of IPSEY stock can currently be purchased for approximately $41.9010.

How big of a company is IPSEN S A/S?

IPSEN S A/S has a market capitalization of $13.88 billion and generates $2.27 billion in revenue each year. The company earns $307.78 million in net income (profit) each year or $0.93 on an earnings per share basis. IPSEN S A/S employs 4,907 workers across the globe.

How can I contact IPSEN S A/S?

IPSEN S A/S's mailing address is 65 quai Georges Gorse, Boulogne-Billancourt cedex I0, 92650. The company can be reached via phone at 33-01-58-33-50-00 or via email at [email protected]


MarketBeat Community Rating for IPSEN S A/S (OTCMKTS IPSEY)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  105 (Vote Outperform)
Underperform Votes:  89 (Vote Underperform)
Total Votes:  194
MarketBeat's community ratings are surveys of what our community members think about IPSEN S A/S and other stocks. Vote "Outperform" if you believe IPSEY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IPSEY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.